| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING FEES | 21,570 | 16,178 | 5,393 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| MORGAN STANLEY SECURITIES | FMV | 4,821,830 | 8,665,122 |
| IVP CALIENT, LLC | AT COST | 15,941 | 15,941 |
| FRANCISCO PARTNERS INVESTMENTS | AT COST | 406,009 | 406,009 |
| BENECHILL, LLC INVESTMENTS | AT COST | 37,495 | 37,495 |
| INTUITIVE CALIENT II, LLC | AT COST | 109,843 | 109,843 |
| CYTORI OFFERING | AT COST | 72,300 | 72,300 |
| INVESTMENT - NEUROTROPE BIO SCIENCE INC | AT COST | 108,000 | 108,000 |
| INVESTMENT - ESKSO BIONICS | AT COST | 40,000 | 40,000 |
| INVESTMENT - NEXTLEVEL SECURITY SYSTEMS | AT COST | 25,000 | 25,000 |
| INVESTMENT - PIERIS PHARMACEUTICALS INC | AT COST | 7,759 | 7,759 |
| INVESTMENT - CUR | AT COST | 20,000 | 20,000 |
| INVESTMENT - ENUMERAL EDI | AT COST | 25,000 | 25,000 |
| US VENTURE PARTNERS XI | AT COST | 153,585 | 153,585 |
| INTUITIVE PEERNOVA | AT COST | 120,558 | 120,558 |
| MEDIA | AT COST | 5,000 | 5,000 |
| HISTOGEN INC | AT COST | 30,396 | 30,396 |
| WILSON SONSINI CALIENT | AT COST | 502,750 | 502,750 |
| INTUITIVE INCODEMA 3D | AT COST | 87,156 | 87,156 |
| SPRUCE DIRECT | AT COST | 4,718 | 4,718 |
| ORPHEUS BIOSCIENCE INC | AT COST | 20,000 | 20,000 |
| INNOVATE BIOPHARMACEUTICALS | AT COST | 8,755 | 8,755 |
| INVESTMENT - US VENTURES XII | AT COST | 268,666 | 268,666 |
| INTUITIVE HZO II, LLC | AT COST | 9,893 | 9,893 |
| OPTICAL CIRCUIT TECH COMPANY | AT COST | 69,079 | 69,079 |
| BLOCK CHANGE TECHNOLOGY | AT COST | 25,000 | 25,000 |
| GROGURU | AT COST | 30,000 | 30,000 |
| CARLSMED INC | AT COST | 25,000 | 25,000 |
| INTUITIVE OSTENDO LLC | AT COST | 24,871 | 24,871 |
| GOGURU INC | AT COST | 20,000 | 20,000 |
| INTUITIVE HZO III, LLC | AT COST | 11,083 | 11,083 |
| US VENTURE PARTNERS XIII | AT COST | 116,763 | 116,763 |
| INTUITIVE ERDIAN | AT COST | 9,973 | 9,973 |
| R4 TECHNOLOGIES | AT COST | 15,000 | 15,000 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| MISCELLANEOUS | 27,415 | 0 | 0 | |
| K-1 INVESTMENT LOSSES | 75,100 | 0 | 0 | |
| PERMITS & LICENSES | 45 | 0 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| OTHER INCOME | 961 | 961 | 961 |
| Description | Amount |
|---|---|
| UNREALIZED GAINS/(LOSSES) | 917,940 |
| Description | Beginning of Year - Book Value | End of Year - Book Value |
|---|---|---|
| INVESTMENT IN ICHOR HOLDINGS | 6,330 | 6,330 |
| INVESTMENT IN QUANTIAMD, LLC | 83,548 | 83,548 |
| INVESTMENT IN ANGION BIOMEDICA CORP | 20 | 20 |
| INVESTMENT IN GEMINI SPACE STATION | 0 | 17,120 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT FEES | 89,993 | 89,993 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX PAID | 3,184 | 3,184 | 0 |